Post Profile






Discovery offers prospect of shorter treatment and cure for chronic myelogenous leukemia

(Dana-Farber Cancer Institute) Although targeted drugs like Gleevec have revolutionized the treatment of chronic myelogenous leukemia, patients generally must take them for the rest of their lives and may cease benefiting from them over time. In new research that could suggest a road to cure, scientists have found that CML stem cells die in response to inhibition of a protein called Ezh2.
read more

share

Related Posts


Bosulif Approved By The FDA For Treatment Of Chronic Myelogenous Leukemia

Health : Medical News Today

The US Food and Drug Administration approved Bosulif as treatment for a rare disease, found in older adults, which attacks the blood and bone marrow and is known as chronic myelogenous leukemia (CML). Approximately 5,430 people will...

Cell Marker Found for Leukemia-Initiating Capacity in Chronic Myelogenous Leukemia

Health : Newswise Medical News

UAB researchers have found a marker on blood cells that may help the most pressing problem in chronic myelogenous leukemia today -- an inability to get patients off treatment. This marker shows heterogeneity among the leukemia stem ...

Existing drugs offer new treatment options for high-risk childhood leukemia subtype

Academics / General Science : ScienceDaily: Science Society

Discovery of the genetic basis of a high-risk subtype of leukemia shows some patients might benefit from existing targeted therapies, advancing the goal of curing all children with the most common childhood cancer

Rutgers Cancer Institute One of Few Centers on East Coast to Offer Immunotherapy Clinical Trial Targeting Leukemia/Lymphoma

Health : Newswise Medical News

Rutgers Cancer Institute of New Jersey is one of a few East Coast sites to offer a clinical trial investigating an experimental drug in the treatment of non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). REGN1979 i...

Synribo (omacetaxine Mepesuccinate) For Myelogenous Leukemia, Approved By FDA

Health : Medical News Today

Synribo (omacetaxine mepesuccinate) has been approved by the FDA (US Food and Drug Administration) for the treatment of chronic myelogenous leukemia (CML) in adult patients. Chronic myelogenous leukemia is also known as chronic myel...

Comments


Copyright © 2016 Regator, LLC